Literature DB >> 6617759

Inhibition of glucocorticosteroid action in cultured L-929 mouse fibroblasts by RU 486, a new anti-glucocorticosteroid of high affinity for the glucocorticosteroid receptor.

I Jung-Testas, E E Baulieu.   

Abstract

The rate of growth of L-929 mouse fibroblasts in vitro is decreased by the glucocorticosteroid dexamethasone (dex) in vitro, as well as cell adhesiveness. These effects were abolished by RU 486, a new synthetic anti-hormone steroid, in both serum-containing medium and serum-free, chemically defined culture medium. RU 486 did not display any glucocorticosteroid-like activity. 3H-RU 486 binds with high affinity (KDeq approximately 0.4 nM) to the same high affinity receptor-binding sites as dex (KD approximately 0.5 nM) in the cell cytosol, as indicated by Scatchard plot, gradient-ultracentrifugation and competition studies. After incubation of whole cells with 3H-RU 486 at 37 degrees C, a radioactive antihormone-receptor complex was found in the nucleus. However, quantitative studies vs 3H-dex indicated that the antagonist provokes less nuclear receptor complex than the agonist.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617759     DOI: 10.1016/0014-4827(83)90282-3

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  20 in total

1.  Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2.

Authors:  Kyoung-Jin Min; Ji Hoon Jang; Jung Tae Lee; Kyeong Sook Choi; Taeg Kyu Kwon
Journal:  J Mol Med (Berl)       Date:  2011-10-19       Impact factor: 4.599

2.  Tissue-specific induction of ADAMTS2 in monocytes and macrophages by glucocorticoids.

Authors:  Thomas P J Hofer; Marion Frankenberger; Jörg Mages; Roland Lang; Peter Meyer; Reinhard Hoffmann; Alain Colige; Löms Ziegler-Heitbrock
Journal:  J Mol Med (Berl)       Date:  2007-12-14       Impact factor: 4.599

Review 3.  Contragestion by antiprogestin RU 486: a review.

Authors:  E E Baulieu; A Ulmann; D Philibert
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

Review 4.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

5.  Regulation of rat liver maturation in vitro by glucocorticoids.

Authors:  J Y Chou; Y J Wan; T Sakiyama
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

6.  Effects of the glucocorticoid antagonist RU486 in spontaneously hypertensive and Sprague Dawley rats.

Authors:  A Soro; M Panarelli; C D Holloway; R Fraser; C J Kenyon
Journal:  J Endocrinol Invest       Date:  1995-12       Impact factor: 4.256

7.  Glucocorticoid receptor stimulation and the regulation of neonatal cerebellar neural progenitor cell apoptosis.

Authors:  Kevin K Noguchi; Karen Lau; Derek J Smith; Brant S Swiney; Nuri B Farber
Journal:  Neurobiol Dis       Date:  2011-04-20       Impact factor: 5.996

8.  Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells.

Authors:  Vanita Gupta; Niranjan Awasthi; B J Wagner
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

9.  RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day.

Authors:  R C Gaillard; A Riondel; A F Muller; W Herrmann; E E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

10.  Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages.

Authors:  M H Abumaree; M A Al Jumah; B Kalionis; D Jawdat; A Al Khaldi; F M Abomaray; A S Fatani; L W Chamley; B A Knawy
Journal:  Stem Cell Rev Rep       Date:  2013-10       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.